Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Key Stats

• Today's Range: $33.51 to $35.10
• 50-Day Range: $27.31 to $41.59
• 52-Week Range: $26.56 to $58.00
• Volume: 445,316 shs
• Average Volume: 475,250 shs
• Market Capitalization: $1.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.33
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 63% of companies evaluated by MarketBeat, and ranked 382nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Establishment Labs has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($2.41) to ($1.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Establishment Labs is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Establishment Labs is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 48.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.14% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Establishment Labs has recently decreased by 8.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.14% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Establishment Labs has recently decreased by 8.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.31

News Sentiment

Establishment Labs has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Establishment Labs this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ESTA on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Establishment Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.09% of the stock of Establishment Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESTA Stock Analysis - Frequently Asked Questions

How have ESTA shares performed this year?

Establishment Labs' stock was trading at $46.07 on January 1st, 2025. Since then, ESTA stock has decreased by 24.8% and is now trading at $34.64.
View the best growth stocks for 2025 here.

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) released its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs's revenue was up 11.3% compared to the same quarter last year.
Read the conference call transcript.

When did Establishment Labs IPO?

Establishment Labs (ESTA) raised $50 million in an initial public offering on Thursday, July 19th 2018. The company issued 3,100,000 shares at $15.00-$17.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and BTIG was co-manager.

Who are Establishment Labs' major shareholders?

Establishment Labs' top institutional shareholders include Brown Advisory Inc. (7.95%), Nantahala Capital Management LLC (6.13%), Rice Hall James & Associates LLC (2.87%) and Boothbay Fund Management LLC (1.83%). Insiders that own company stock include Nicholas Sheridan Lewin, Quiros Juan Jose Chacon, Raj Denhoy, Raj Denhoy and Leslie Gillin.
View institutional ownership trends.

How do I buy shares of Establishment Labs?

Shares of ESTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Establishment Labs investors own include PayPal (PYPL), NVIDIA (NVDA), Walt Disney (DIS), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/31/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 960
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $55.33
• High Stock Price Target: $70.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +59.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.50 million
• Net Margins: -46.13%
• Pretax Margin: -46.87%
• Return on Equity: -184.55%
• Return on Assets: -24.81%

Debt

• Debt-to-Equity Ratio: 5.94
• Current Ratio: 3.62
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $170.24 million
• Price / Sales: 5.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 48.79

Miscellaneous

• Outstanding Shares: 28,917,000
• Free Float: 24,795,000
• Market Cap: $1.00 billion
• Optionable: Optionable
• Beta: 0.73